Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)
Researchers on high-dose tirzepatide (10-15 mg) typically begin retatrutide at 4-8 mg rather than the standard 2 mg starting dose, since their GI tract is already adapted to incretin receptor activation
As a peptide supplier with certificate of analysis , we are the go-to Peptide Sciences alternative trusted by the research community
The drug is supposed to make you healthier, not just lighter
It may go without saying, but the old-fashioned way diet and exercise remains a preferred weight loss method
